WO2000024429A3 - Compound - Google Patents

Compound Download PDF

Info

Publication number
WO2000024429A3
WO2000024429A3 PCT/GB1999/003488 GB9903488W WO0024429A3 WO 2000024429 A3 WO2000024429 A3 WO 2000024429A3 GB 9903488 W GB9903488 W GB 9903488W WO 0024429 A3 WO0024429 A3 WO 0024429A3
Authority
WO
WIPO (PCT)
Prior art keywords
state
compound
contrast
oxidation
relaxivity
Prior art date
Application number
PCT/GB1999/003488
Other languages
French (fr)
Other versions
WO2000024429A2 (en
Inventor
Kenneth Kellar
Original Assignee
Nycomed Imaging As
Golding Louise
Kenneth Kellar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Imaging As, Golding Louise, Kenneth Kellar filed Critical Nycomed Imaging As
Priority to AU63535/99A priority Critical patent/AU6353599A/en
Priority to EP99950946A priority patent/EP1123116A2/en
Publication of WO2000024429A2 publication Critical patent/WO2000024429A2/en
Publication of WO2000024429A3 publication Critical patent/WO2000024429A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)

Abstract

The invention relates to the use as a contrast agent in MR imaging of a physiologically tolerable lanthanide compound or salt thereof having first and second oxidation states which differ in relaxivity by a factor of at least 5, and which is convertible in vivo from said first to said second oxidation state whereby contrast is enhanced in a body region in which conversion to said second state does or does not occur.
PCT/GB1999/003488 1998-10-22 1999-10-22 Compound WO2000024429A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU63535/99A AU6353599A (en) 1998-10-22 1999-10-22 Compound
EP99950946A EP1123116A2 (en) 1998-10-22 1999-10-22 Contrast agents with variable oxidation states

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9823175.6A GB9823175D0 (en) 1998-10-22 1998-10-22 Compound
GB9823175.6 1998-10-22
US10721298P 1998-11-05 1998-11-05

Publications (2)

Publication Number Publication Date
WO2000024429A2 WO2000024429A2 (en) 2000-05-04
WO2000024429A3 true WO2000024429A3 (en) 2000-10-19

Family

ID=10841125

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/003488 WO2000024429A2 (en) 1998-10-22 1999-10-22 Compound

Country Status (4)

Country Link
EP (1) EP1123116A2 (en)
AU (1) AU6353599A (en)
GB (1) GB9823175D0 (en)
WO (1) WO2000024429A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8679453B2 (en) 2009-07-13 2014-03-25 Universidad De Guanajuato Contrast agents

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0450742A1 (en) * 1990-04-06 1991-10-09 Schering Aktiengesellschaft DTPA-Monoamids, pharmaceutical compositions containing them, their use and process for their preparation
WO1994027977A1 (en) * 1993-05-28 1994-12-08 Schering Aktiengesellschaft Use of macrocyclic metal complexes as temperature probes
DE19507822A1 (en) * 1995-02-21 1996-08-22 Schering Ag New di:ethylene-tri:amine penta:acetic acid amide derivs. and complexes
WO1996038184A2 (en) * 1995-06-02 1996-12-05 Research Corporation Technologies, Inc. Magnetic resonance imaging agents for the detection of physiological agents
WO1998047539A1 (en) * 1997-04-22 1998-10-29 Nycomed Imaging As Nmr image compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0450742A1 (en) * 1990-04-06 1991-10-09 Schering Aktiengesellschaft DTPA-Monoamids, pharmaceutical compositions containing them, their use and process for their preparation
WO1994027977A1 (en) * 1993-05-28 1994-12-08 Schering Aktiengesellschaft Use of macrocyclic metal complexes as temperature probes
DE19507822A1 (en) * 1995-02-21 1996-08-22 Schering Ag New di:ethylene-tri:amine penta:acetic acid amide derivs. and complexes
WO1996038184A2 (en) * 1995-06-02 1996-12-05 Research Corporation Technologies, Inc. Magnetic resonance imaging agents for the detection of physiological agents
WO1998047539A1 (en) * 1997-04-22 1998-10-29 Nycomed Imaging As Nmr image compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DESSER T S ET AL: "DYNAMICS OF TUMOR IMAGING WITH GD-DTPA-POLYETHYLENE GLYCOL POLYMERS: DEPENDENCE ON MOLECULAR WEIGHT", JOURNAL OF MAGNETIC RESONANCE IMAGING,US,OAK BROOK, IL, vol. 4, no. 3, 1 May 1994 (1994-05-01), pages 467 - 472, XP000576804 *
GUNNLAUGSSON, THORFINNUR ET AL: "Luminescent europium tetraazamacrocyclic complexes with wide range pH sensitivity", CHEM. COMMUN. (CAMBRIDGE) (1998), (4), 511-512, - February 1998 (1998-02-01), XP002136097 *

Also Published As

Publication number Publication date
WO2000024429A2 (en) 2000-05-04
GB9823175D0 (en) 1998-12-16
EP1123116A2 (en) 2001-08-16
AU6353599A (en) 2000-05-15

Similar Documents

Publication Publication Date Title
CA2268324A1 (en) Administrable compositions and methods for magnetic resonance imaging
EP2071040A3 (en) Diagnostics and therapeutics for vascular disease
AU1818695A (en) Gas-containing microcapsules useful as contrast agents for diagnostic imaging
HUP0100159A3 (en) Compounds for the antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition
WO2001092283A3 (en) Cobalamin compounds useful as cardiovascular agents and as imaging agents
AU2001249835A1 (en) Diagnosis and treatment of alzheimer's disease
AU6566794A (en) Use of dihydroliponic acid as an ophthalmologic agent and for the suppression of incompatability reactions at the interfaces between implants and living body tissue
WO2001066564A3 (en) Gamma-secretase inhibitors
WO2001021159A3 (en) Pharmaceutical composition of nateglinide and another antidiabetcagent
WO2002100442A3 (en) Use of l-polynucleotides and derivatives thereof for in vivo imaging
EP2767291A3 (en) Treatment of glycogen storage disease type II
CA2299504A1 (en) Antibodies to oxidation-specific epitopes on lipoprotein and methods for their use in detecting, monitoring and inhibiting the growth of atheroma
AU5314694A (en) New agents for diagnosis of vascular diseases
CA2326339A1 (en) Use of dexmedetomidine for icu sedation
HUP9900426A3 (en) Amyloid binding azoderivatives, preparation thereof and use of these compounds for the antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition
IL158155A (en) Use of erythropoietin for the preparation of a medicament to ameliorate chemotherapy-induced toxicity
AU2001257406A1 (en) Methods and compositions for the diagnosis and treatment of cardiovascular and tumorigenic disease using 4941
WO2000024429A3 (en) Compound
WO2002092044A3 (en) Use of electrolytes for reinforcing the barrier function of the skin
AU2002222108A1 (en) Diagnosis and treatment of alzheimer's disease
ZA200105539B (en) Compositions comprising at least one mono- or polycarbonyl self-tanning agent and a flavylium salt compound which is unsubsituted in postion 3, for colouring the skin, and uses thereof.
FI965094A0 (en) 2,4,6-Triiodo-5-substituted aminoisophthalate esters useful as contrast agents in medical diagnostic imaging
CA2241825A1 (en) New monofunctionalized edta, dtpa and ttha derivatives and their use in medical diagnosis and therapy
CA2399709A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid and/or physiologically compatible salts thereof for producing a medicament for treating cancers
CA2371178A1 (en) Prucalopride oral solution

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 1999 63535

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1999950946

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09830147

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999950946

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999950946

Country of ref document: EP